Literature DB >> 19768724

Neuropsychiatric symptoms in Parkinson's disease.

Dag Aarsland1, Laura Marsh, Anette Schrag.   

Abstract

Neuropsychiatric symptoms are common in Parkinson's disease, even at the earliest stages, and have important consequences for quality of life and daily functioning, are associated with increased carer burden and increased risk for nursing home admission. In addition to cognitive impairment, a wide range of neuropsychiatric symptoms have been reported. In this article, the epidemiology, clinical course, diagnosis, and management of some of the most common neuropsychiatric symptoms in PD are discussed: depression, anxiety, apathy, fatigue, and psychotic symptoms. Although much is known regarding the prevalence and course of these symptoms, the empirical evidence for how to manage these symptoms is limited at best. There is thus an urgent need for systematic studies for the pharmacological and non-pharmacological management of these symptoms.

Entities:  

Mesh:

Year:  2009        PMID: 19768724      PMCID: PMC2787875          DOI: 10.1002/mds.22589

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  89 in total

1.  Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial.

Authors:  Dan A Mendonça; Krishe Menezes; Mandar S Jog
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

2.  Impact of fatigue in Parkinson's disease: the Fatigue Impact Scale for Daily Use (D-FIS).

Authors:  Pablo Martinez-Martin; Maria Jose Catalan; Julian Benito-Leon; Angel Ortega Moreno; Ivana Zamarbide; Esther Cubo; Nadeje van Blercon; Victor Campos Arillo; Margarita Pondal; Gurutz Linazasoro; Fernando Alonso; Pedro García Ruiz; Belen Frades
Journal:  Qual Life Res       Date:  2006-05       Impact factor: 4.147

3.  Fatigue in patients with Parkinson's disease.

Authors:  K Karlsen; J P Larsen; E Tandberg; K Jørgensen
Journal:  Mov Disord       Date:  1999-03       Impact factor: 10.338

4.  Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.

Authors:  R Pahwa; M A Stacy; S A Factor; K E Lyons; F Stocchi; B P Hersh; L W Elmer; D D Truong; N L Earl
Journal:  Neurology       Date:  2007-04-03       Impact factor: 9.910

5.  Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease.

Authors:  Valeria Isella; Paola Melzi; Marco Grimaldi; Simona Iurlaro; Roberto Piolti; Carlo Ferrarese; Lodovico Frattola; Ildebrando Appollonio
Journal:  Mov Disord       Date:  2002-03       Impact factor: 10.338

Review 6.  Anxiety disorders in Parkinson's disease.

Authors:  Irene H Richard
Journal:  Adv Neurol       Date:  2005

7.  Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.

Authors:  William G Ondo; Thomas Perkins; Todd Swick; Keith L Hull; J Ernesto Jimenez; Tippy S Garris; Daniel Pardi
Journal:  Arch Neurol       Date:  2008-10

8.  Parkinson's disease and anxiety: comorbidity with depression.

Authors:  M A Menza; D E Robertson-Hoffman; A S Bonapace
Journal:  Biol Psychiatry       Date:  1993-10-01       Impact factor: 13.382

9.  Anxiety disorders in patients with Parkinson's disease.

Authors:  M B Stein; I J Heuser; J L Juncos; T W Uhde
Journal:  Am J Psychiatry       Date:  1990-02       Impact factor: 18.112

10.  Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study.

Authors:  Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt
Journal:  Mov Disord       Date:  2003-10       Impact factor: 10.338

View more
  117 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  Parkinson disease: Depression and anxiety in Parkinson disease.

Authors:  Pablo Martínez-Martín; Javier Damián
Journal:  Nat Rev Neurol       Date:  2010-05       Impact factor: 42.937

Review 3.  The Therapeutic Potential of Exercise to Improve Mood, Cognition, and Sleep in Parkinson's Disease.

Authors:  Gretchen O Reynolds; Michael W Otto; Terry D Ellis; Alice Cronin-Golomb
Journal:  Mov Disord       Date:  2015-12-30       Impact factor: 10.338

4.  Adjustment disorder and risk of Parkinson's disease.

Authors:  E Svensson; D K Farkas; J L Gradus; T L Lash; H T Sørensen
Journal:  Eur J Neurol       Date:  2016-01-12       Impact factor: 6.089

Review 5.  Stress, depression and Parkinson's disease.

Authors:  Ann M Hemmerle; James P Herman; Kim B Seroogy
Journal:  Exp Neurol       Date:  2011-10-06       Impact factor: 5.330

6.  Therapeutic application of neural stem cells and adult neurogenesis for neurodegenerative disorders: regeneration and beyond.

Authors:  Sarah E Latchney; Amelia J Eisch
Journal:  Eur J Neurodegener Dis       Date:  2012

Review 7.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

Review 8.  [Depression and neurological diseases].

Authors:  D Piber; K Hinkelmann; S M Gold; C Heesen; C Spitzer; M Endres; C Otte
Journal:  Nervenarzt       Date:  2012-11       Impact factor: 1.214

9.  Evaluation and management of the non-motor features of Parkinson's disease.

Authors:  Steven Wishart; Graeme J A Macphee
Journal:  Ther Adv Chronic Dis       Date:  2011-03       Impact factor: 5.091

Review 10.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.